Gene therapy technologies are inevitably required to boost the therapeutic performance of cell therapies; thus, validating the efficacy of gene carriers specifically used for preparing cellular therapeutics is a prerequisite for evaluating the therapeutic capabilities of gene and cell combinatorial therapies. Herein, the efficacy of a recombinant adeno-associated virus derivative (rAAVr3.45) was examined to evaluate its potential as a gene carrier for genetically manipulating interleukin-10 (IL10)-secreting human neural stem cells (hNSCs) that can potentially treat ischemic injuries or neurological disorders. Safety issues that could arise during the virus preparation or viral infection were investigated; no replication-competent AAVs were detected in the final cell suspensions, transgene expression was mostly transient, and no severe interference on endogenous gene expression by viral infection occurred. IL10 secretion from hNSCs infected by rAAVr3.45 encoding IL10 did not alter the transcriptional profile of any gene by more than threefold, but the exogenously boosted IL10 was sufficient to provoke immunomodulatory effects in an ischemic brain injury animal model, thereby accelerating the recovery of neurological deficits and the reduction of brain infarction volume. This study presents evidence that rAAVr3.45 can be potentially used as a gene carrier to prepare stem cell therapeutics.
Introduction
Ex vivo cell therapy strategies, which involve the exogenous delivery of therapeutic genes into therapeutically relevant cultured cells for their subsequent administration into the body, must have safe and efficient gene carriers to increase their therapeutic efficacy. In this context, due to their inherently safe and non-pathogenic features, adeno-associated virus (AAV) has been considered as a powerful gene vector in many gene therapy trials to treat a variety of inherited or acquired human diseases, including spinal muscular atrophy [1] , retinal dystrophy [2] , hemophilia A/B [3] , Parkinson's disease [4] , and Leber's congenital amaurosis [5] . The recent approvals of AAV-based gene therapy products by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) further confirm the therapeutic and safe performance of AAV vectors [6] . Furthermore, the genome-editing approaches recently adopted AAV systems to efficiently deliver their genome-editing cassettes into target cells in vivo [7, 8] . Thus, recent many gene therapy trials using AAV vectors have gained worldwide attention due to their superior safety and efficacy [9, 10] .
To further boost the therapeutic capacity of AAV vectors, attempts have been made to address several key challenges associated with the naive AAV serotypes, such as These authors contributed equally: Mira Cho, Kwangsoo Jung innate immunogenicity or limited tropism, by engineering novel AAV capsid constructs [11] [12] [13] . Many AAV derivatives emerged from the design of new capsid architectures via genetic modification or chemical decorations [11, 12, [14] [15] [16] [17] . The unique features of the AAV derivatives compared with naturally occurring AAV serotypes, such as specific tropism [12, 13] , reduced immunity [11] , or enhanced gene delivery [12, 18] , will further broaden the application scopes of AAV-mediated gene therapy approaches. To trigger their successful translation into human clinical use, the safety-and efficacy-related issues involved in the characteristics of AAV derivatives and their therapeutic capabilities must be thoroughly investigated.
In this study, the feasibility of an AAV derivative, AAVr3.45, for safely preparing ex vivo neural stem cell therapeutics was examined. The AAVr3.45 was developed as a gene carrier from the AAV2 capsid frame to efficiently transduce neural stem cells (NSCs) [12] , and its capability to circumvent human neutralizing antibody inactivation, which is highly critical to boost its therapeutic performance in human trials [19] , has been recently verified [20] . Additionally, a variety of previous studies demonstrated their capabilities that can be used in many biomedical applications, including tissue engineering [21] , cancer therapy [20] , and gene therapy [22, 23] . In this study, human NSCs (hNSCs), which were isolated from a human fetal brain (HFT13) [24] , were used as target cells to assess the safety issues involved in AAVr3.45 infection and its efficacy as a gene carrier to prepare hNSC therapeutics (referred as HFT13-hNSCs). Importantly, due to the intrinsic limitations of naive AAV serotypes, which lack gene delivery capacity for many stem cell types, AAVmediated ex vivo stem cell therapy trials have not been frequently performed [12, 25] . Thus, providing guidelines for safely and efficiently preparing stem cell therapeutics using AAVr3.45 vectors can significantly contribute to the translation of AAV derivative-mediated stem cell therapy approaches into clinical use.
To establish the quality assurance (QA) of viral vectors/ genetically modified stem cells, detrimental effects that can occur during the viral/cellular preparation processes, such as contamination of replication-competent virus in final viral stocks and the presence of free viruses floating in final cell suspensions, were investigated. Key safety aspects, including persistent/transient gene expression, viral genome insertion into the host genome, in vivo bio-distribution, and interference in endogenous gene expression after viral infection, were further examined. Finally, the therapeutic performance of recombinant AAVr3.45 vectors carrying the human interleukin-10 gene (rAAVr3.45-IL10) infecting HFT13-hNSCs to secrete IL10 into the extracellular environment was evaluated. Overexpression of IL10 can serve as a neuroprotective agent against hypoxic-ischemic (HI) neuronal death [26, 27] and suppress acute immune responses at a lesion in the early stages of cellular administration [28, 29] . Thus, the secretion of IL10 from HFT13 cells that are safely infected by rAAVr3. 45 can be a strategy to elicit immunomodulation upon cellular transplantation, thereby inhibiting dendritic cell infiltration into the lesion sites and consequently promoting the survival rates of exogenously transplanted foreign stem cells [30, 31] . The functional efficacy of the IL10 from HFT13-hNSCs infected by rAAVr3.45-IL10 was assessed in a HI brain injury mouse model by monitoring the recovery of brain infarction and neurological deficits. The results of this study demonstrate the safety and efficacy of an AAV variant that can be employed for producing NSC therapeutics, possibly providing evidence for translating its use to the clinical treatment of many neurological disorders, such as ischemic brain or spinal cord injuries.
Results
The safety and efficacy issues that can be encountered during the packaging of the AAV derivative AAVr3. 45 or that can be caused by viral infection (i.e., genome insertion or aberrant transcription) were examined to evaluate its potential as a gene therapy agent for preparing ex vivo hNSC therapeutics. Possible adverse issues involved in the general processes for preparing viruses and genetically modified cell products, such as bacterial contamination of final viral suspension, the emergence of replicationcompetent AAV (rc-AAV), viral genome insertion into the host chromosomes, and interference against endogenous gene expression, were initially investigated to assess the suitability of AAVr3.45 vectors for future human applications (Fig. 1a) . The efficacy of AAVr3.45-mediated infection was further examined by monitoring viral stability and the viral gene expression profiles over time. Finally, the functional analysis of interleukin-10 (IL10) gene expression, which was exogenously boosted by the infection of rAAVr3.45 coding for IL10 (rAAVr3.45-IL10), were further studied in a neonatal HI brain injury animal model (Fig. 1a) .
The contamination of the final viral suspension with mycoplasma was assessed prior to infecting cells. Because agents required for a density-gradient AAV purification (i.e., iodixanol) or buffer-exchanging filters could not be fully sterilized due to technical limitations, ensuring the absence of bacteria in the final viral suspension was necessary for validating the quality of viral samples prior to viral infection. This quality validation of viral suspensions can be critical because antibiotics are typically excluded from the majority of stem cell-based cellular therapeutics for clinical trial purposes [32, 33] . The culture medium containing AAV-293 cells prior to viral infection and the final viral suspensions were collected, and trace mycoplasma in each solution was amplified by polymerase chain reaction (PCR) with primers specific to the conserved region of 16S ribosomal mycoplasma RNA (16S rRNA) [34] . No bands corresponding to the 16S rRNA of mycoplasma were detected in any viral final product or packaging cell line ( Figure S1A ). Mycoplasma contamination can significantly disturb the cellular metabolic activities and cause fatal errors in DNA replication and protein synthesis [35, 36] , thereby affecting viral yields [37] . Thus, confirming the clearance of bacterial contamination can be a mandatory task that is closely related to both the safety and efficacy issues involved in viral preparation processes.
Subsequently, the capability of AAVr3.45 vectors to infect HFT13-hNSCs was examined. Recombinant AAV vectors (rAAV) lacking the rep gene and carrying a transgene cassette comprising the cytomegalovirus (CMV) promoter-human β-globin (HBB)-green fluorescent protein (GFP)-polyadenylation (polyA) sequence flanked by inverted terminal repeats (ITRs) (rAAVr3.45-GFP; Fig. 1b , were packaged by an adenovirus-free plasmid transfection method followed by a density-gradient purification. Two representative wild-type rAAV vectors (i.e., rAAV2-GFP and rAAV5-GFP), which have been widely used in many gene therapy applications [9] , were chosen as control vectors. Viral vectors' infectious properties were determined by quantifying the percentages of GFP-expressing cells out of the total number of cells. Over 90.0% of HFT13-hNSCs expressed GFP when cells were infected at genomic multiplicities of infection (MOI) ranging from 5.0 × 10 3 to 1.0 × 10 4 , whereas no apparent GFP expression was observed in HFT13-hNSC infection by AAV2 or AAV5 (Fig. 1c) . The superior performance of AAVr3.45 vectors for efficiently infecting NSCs, which was further confirmed in a different hNSC type that was isolated from the rep gene in the lysates of HEK293T cells that were co-infected with the designated rAAV-GFP vectors and rc-AAV/Ad5. Additional round of HEK293T cell infection was performed using the viral samples in the cell lysates collected from the first round of infection, and all processes to amplify the rep genes were conducted identically to the first round of cellular infection. The symbol * indicates significant differences between the rc-AAV2 group and other groups (P < 0.001). There were no significant differences between the adenovirusonly group and other rAAV groups. (P > 0.05) diencephalon [24] (Figure S1B ; over 75.0% at genomic MOI of 4.0 × 10 3 and 1.0 × 10 4 ), is consistent with the data observed in a previous study [12] .
Next, the contamination of rc-AAV in the suspensions containing cells that were infected by rAAV vectors (i.e., replication-incompetent) was examined to further validate the safety of rAAVr3.45-mediated gene delivery (Fig. 1d) . In the presence of helper viruses, such as adenovirus or herpes simplex virus, the reactivation of capsid assembly within the host cells is initiated to generate rc-AAV vectors, which can elicit safety concerns due to the rapid propagation of the infectious virion throughout the body [38] . The presence of rc-AAVr3.45 in the final cell suspension was examined in parallel with those of rc-AAV2 or rc-AAV5. Because neither AAV2 nor AAV5 is infectious to HFT13-hNSCs, the existence of rc-AAV vectors was checked in a human embryonic kidney cell line (HEK293T), which is mostly permissive to wild-type AAVs. HEK293T cells infected by each rAAV-GFP vector were co-infected with wild-type adenovirus 5 (Ad5) to initiate the synthesis of rc-AAV shells, whose genomic fragments might be occasionally carried in episomal forms or integrated into the host. The co-infected cells were lysed, and viral genomic DNA, specifically the rep gene, was rescued from both the supernatant and lysates for quantitative PCR (qPCR) analysis. Importantly, to further check the absence of rc-AAV, the lysates obtained from the first-round infection were reutilized for the second-round infection of HEK293T cells, which were additionally co-infected with Ad5 to further rescue the small fractions of rc-AAV that might exist in the suspension collected from the first round of infection. Thus, the qPCR analysis of the rep gene was performed using the lysates collected at each round of infection. While substantial amplification of the rep gene was observed upon infection with rc-AAV2, no rep genes were detected in the lysates obtained at each round of infection when cells were infected by any one of the rAAV vectors (i.e., rAAV2-GFP, rAAV5-GFP, or rAAVr3.45-GFP) (Fig. 1d) . These data further show that the risks associated with rAAVr3.45-mediated gene delivery were limited.
Another possible safety issue can be the presence of free viruses floating in the final cell suspensions because free virus can cause off-target spreading upon cellular administration into the body. Thus, HFT13-hNSCs infected with high gene delivery efficiencies ( > 80 GFP%) by rAAVr3.45-GFP vectors at a genomic MOI of 1 × 10 4 were rinsed three times, and the infectious profiles of the free viral vectors, which were rescued from the supernatant collected at each washing step, were assessed for HEK293T cell infection. Significant reductions in GFP percentage by each viral residue were seen after the second round of rinsing (i.e., 31.4-1.57%), and no apparent GFP signals (0.23-0.101%) were observed thereafter ( Figure S1C ), indicating the necessity of at least two cell-rinsing steps to exclude free viral vectors from the cell suspensions prior to preparing final cell products.
The stability of rAAVr3.45 vectors against temperature variations, which can be highly critical for mass manufacturing and global delivery, was evaluated. Initially, three sets of each viral vector (rAAV2-, rAAV5-, and rAAVr3.45-GFP) were stored at 4, −20, and −80°C, respectively, completely thawed at room temperature after 1 week, and used for infecting HEK293T cells at a genomic MOI of 1 × 10 3 . No significant differences in gene delivery profiles (GFP %) were observed between the three viral sets stored at each temperature ( Figure S2A ). Importantly, the infectious properties of viral vectors that were exposed to relatively harsh conditions (25°C and 37°C) for 5 days were partially conserved; no significant differences in infectious properties of any rAAV vector stored at 25°C were observed compared with those obtained by viral samples stored at 4°C, but dramatic reductions in GFP signals from cells infected by rAAV vectors stored at 37°C for 5 days were detected ( Figure S2B ). These decreases in infectious properties of viral vectors stored at 37°C indicate that viral vectors must be kept at low temperature to maintain their durability as commercialized gene therapy products.
Based on the physical features of rAAVr3.45 vectors (i.e., organ specificity, stability) and safety aspects that can be observed during viral packaging steps, additional critical issues associated with rAAVr3.45-mediated cellular infection were further examined. The persistence of transgene expression and the viral genome integration into the host chromosomes were assessed. Initially, the duration of rAAVr3.45-mediated gene expression in HFT13-hNSCs was monitored; overall, the expression was transient. Because the transduction efficiencies of rAAV2 and rAAV5 vectors are inherently too low in HFT13-hNSCs, the gene expression profiles in HEK293T cells were examined in parallel. Thus, only rAAVr3.45-GFP vectors were used to monitor the time-dependent gene expression in HFT13-hNSCs. In HEK293T cells, all viral infections resulted in nearly identical profiles; maximum GFP expression was seen at early time points ( < 5 days) with subsequent reductions in the proportions of GFP-expressing cells and nearly background levels of GFP signal after 10 days (Fig. 2a) . Similarly, the initial levels of gene expression in HFT13-hNSCs were nearly saturated (91.7 ± 1.18%) by infecting cells with rAAVr3.45-GFP vectors at a genomic MOI of 1 × 10 4 ; the proportion of GFP-expressing cells steeply declined until 28 days post-transduction and persisted weakly thereafter (Fig. 2b ). As shown in Fig. 2c , the majority of HFT13-hNSC clusters robustly emitted GFP signals at early stages ( < 7 days), but both the fractions and the intensities of GFP signals were simultaneously reduced as time increased, implying transient gene expression. Interestingly, after 28 days, small fractions of HFT13-hNSCs, which were split for sub-culturing every week, continuously emitted light GFP signals for at least 100 days (data not shown; compared with background levels, P < 0.01), suggesting the possibility of viral genome integration into the host chromosomes.
To investigate the cause of the weak persistent gene expression, HFT13-hNSCs emitting GFP signals were sorted 2 months after transduction, and their chromosomal DNA was extracted to analyze the whole-genome sequence by high-throughput next-generation sequencing (NGS, Sequence Read Archive (SRA) database "SRA: SRR5574094"). For NGS, the genomic DNA of the HFT13-hNSCs, including the locus containing the integrated viral genome (i.e., any parts of ITR-CMV-HBB-GFP-PolyA-ITR), is fragmented into approximately 150-200-base-pair fragments to align library junction sequences [39] . Reporting the complete evidence of whole-viralgenome insertion at specific chromosome sites and the frequencies of random vs. site-specific viral insertions is technically limited using the NGS analysis [40] . Instead, the location of chromosomal sequences where any fragments of viral genomes are discovered can be identified. Here, the viral genome fragments carried by rAAVr3.45-GFP vectors were found in 13 different chromosomal sites (Table 1) . Interestingly, the majority of integrated sites were located on non-transcriptionally active intron sites (Table 1) , except for a locus of HBB on chromosome 11 (11p15.4), which primarily functions in the production of hemoglobin [41] . More vigorous studies on the beneficial or detrimental effects of viral genome insertion into the chromosomal HBB site must be further conducted to ensure the safety of rAAVr3.45-mediated gene delivery. The AAV integration site 1 (AAVS1) on chromosome 19 (19q13.31) , which is regarded as a safe-harbor site for gene knock-in by AAV infection [42, 43] , was also listed in the loci containing the viral genome.
Next, to evaluate the therapeutic potential of rAAVr3.45 vectors for preparing cellular therapeutics, rAAVr3.45 vectors carrying human IL10 were newly designed and delivered to HFT13-hNSCs, which were ultimately transplanted into HI brain injury mouse models. Thus, in addition to the regenerative performance of HFT13-hNSCs, the immunomodulatory effects at the infarction sites by the IL10 secreted from HFT13-hNSCs were evaluated in terms of treating the neurological deficits that occurred in the HI animal models. Bicistronic rAAVr3.45 vectors, in which upstream IL10 gene expression was driven by the CMV promoter and the downstream GFP gene was translated, were generated by inserting an internal ribosome entry site (IRES) between the IL10 and GFP genes (rAAVr3.45-IL10- (3, 7, 14, 22 , and 28 days). Symbols * and ** indicate significant differences compared with (a) GFP percentages by rAAV2-GFP or rAAV5-GFP (P < 0.01) and (b) background levels (P < 0.01), respectively. Scale bar, 100 μm IRES-GFP; Fig. 3a) . Thus, both the location and the extent of the cellular transduction by rAAVr3.45 carrying IL10 could be readily monitored by simply detecting GFP signals. The rAAVr3.45-GFP vectors (no IL10) were employed as controls. The GFP expression profiles in HFT13-hNSCs by rAAVr3.45-IL10-IRES-GFP vectors were initially analyzed. When HFT13-hNSCs were infected by rAAVr3.45-IL10-IRES-GFP at the genomic MOI of 1 × 10 4 , strong GFP signals ( > 80%) were detected after viral infection, peaking at 3-5 days post-transduction and lasting until 14 days, but the number of GFP-expressing cells was distinctly attenuated after 3-4 weeks (Fig. 3b) . Based on the results shown in Fig. 3b and those of rAAVr3.45-GFP that induced saturated GFP expression ( > 85%; Figs. 1c and 2b), the genomic MOI of rAAVr3.45-IL10-IRES-GFP vectors was set to 1 × 10 4 and used to examine the therapeutic performance of IL10 secreted from HFT13-hNSCs. The quantity of IL10 secreted from 1 × 10 6 HFT13-hNSCs at 2 days and 5 days post-transduction corresponded to approximately 10.1 ± 2.0 ng and 49.9 ± 18.1 ng, respectively (Fig. 3c) . The western blot analysis confirmed that IL10 was mostly secreted into the supernatant rather than remaining in the intracellular level (Fig. 3d) ; highly dense bands corresponding to the secreted IL10 in the supernatant were observed compared with those for the IL10 that was extracted from the cell lysate. No apparent bands corresponding to IL10 were detected in the controls: cells only (no viral infection) and cells infected by rAAVr3.45-GFP (Fig. 3d) . The enhanced immunomodulatory ability of IL10-secreting HFT13-hNSCs (i.e., infected by rAAVr3.45-IL10-IRES-GFP) compared with GFP-expressing HFT13-hNSCs (i.e., infected by rAAVr3.45-GFP) was confirmed by assessing the significant inhibition of tumor necrosis factor-α (TNF-α) production from microglial cell line (SIM-A9) stimulated by LPS (10 or 100 ng/mL) ( Figure S3 The in vivo therapeutic performance of IL10-secreting HFT13-hNSCs was determined by evaluating neurological function tests of HI brain-injured mice and by measuring the reduced volume of infarction. Consequently, transplantation of IL10-secreting HFT13-hNSCs (infected by rAAVr3.45-IL10-IRES-GFP at a genomic MOI of 1 × 10 4 , n = 12) resulted in significant improvement in neurological function tests (i.e., lower neurological severity scores) compared with vehicle injection (i.e., injection of H-H buffer (Hanks's balanced salt solution containing 10 mM HEPES), n = 6; P < 0.01) at 1, 2, 3, and 4 weeks posttransplantation and to GFP-expressing HFT13-hNSCs (infected by rAAVr3.45-GFP, n = 16; P < 0.05) at 1 and 4 weeks post-transplantation (Fig. 4a) . Furthermore, at 4 weeks post-transplantation, the HI brain-injured mice that were transplanted with IL10-secreting HFT13-hNSCs (n = 9) demonstrated significantly reduced infarction volume compared with the ones treated with vehicle only (n = 8; P < 0.05, Fig. 4b ). The reduction of infarction volume was indicated as the ratio of the infarct volume to that of the contralateral hemisphere. No significant differences in infarction volume were observed in mice treated with vehicle only and the ones treated with GFP-expressing HFT13-hNSCs (Fig. 4b) . Body weight changes are not typically observed in HI brain-injured animals [44] , and the body weights of all three groups were not significantly different over 4 weeks (Fig. 4c) . The lack of significant changes in body weight might indicate that both exogenously boosted IL10 secretion and human cell infusion into mice did not cause detrimental effects on mouse vitality. Importantly, numerous GFP-positive HFT13-hNSCs, which were observed in the peri-infarct region at 2 weeks post-transplantation, simultaneously expressed IL10 (hIL10) and human-specific cytoplasm (STEM121), suggesting that many portions of the transplanted HFT13-hNSCs were well integrated into the host (Fig. 4d) . Compared with the results obtained by transplanting HFT13-hNSCs only (i.e., infected by rAAVr3.45-GFP), the significant improvement in neurological recovery and the reduction in infarction volume by transplanting the IL10-secreting HFT13-hNSCs potentially indicate the synergistic potential of the IL10′s immunomodulatory ability at the lesion site and hNSCs' regenerative capability for the treatment of a variety of neurological disorders. Finally, a key aspect that can be considered upon exogenously overexpressing IL10 in HFT13-hNSCs, which suggests possible interference with cellular transcription, was examined by messenger RNA (mRNA) microarray analysis to quantify cellular gene expression after viral infection (Gene Expression Omnibus database "GEO: Fig. 5a ). It was assumed that expressing a therapeutic gene rather than a reporter gene and subsequently evaluating the effects of the # exhibits a significant difference between rAAVr3.45-GFP-and rAAVr3.45-IL10-IRES-GFP-treated groups (*P < 0.01; **P < 0.001; # P < 0.05). The data represent the mean ± SEM. b Effect of IL10-secreting HFT13-hNSCs transplantation on infarction volume in HI brain injury (infected by rAAVr3.45-IL10-IRES-GFP: n = 9, rAAVr3.45-GFP: n = 9, by vehicle: n = 8). The infarct volume indicates its ratio to the volume of the contralateral hemisphere. *P < 0.05. The data represent the mean ± SD. c Measurement of body weight. The data represent the mean ± SD. d Transplantation of IL10-and GFPexpressing HFT13-hNSCs into the HI-injured brain in neonatal mice. Grafted GFP-positive HFT13-hNSCs (green) expressed both interleukin-10 (red; hIL10) and human-specific cytoplasm (white; STEM121) in the peri-infarct region of the HI brain injury. All nuclei were stained with DAPI (blue) (color figure online) transgene expression only on the cellular transcription levels would be a crucial approach that better approximated the clinical setting. Additional rAAVr3.45 vectors were produced as controls: rAAVr3.45 vectors having no transgene (rAAVr3.45-mock), which were used to examine the disruption in cellular gene expression by viral infection itself, were also newly packaged (right panel of Fig. 5a ). Prior to mRNA microarray analysis using rAAVr3.45-IL10 vectors, the genomic MOIs of rAAVr3.45-IL10 vectors needed to secrete decent levels of IL10, corresponding to the quantity that successfully induced functional recovery in HI brain-injured mouse models by rAAVr3.45-IL10-IRES-GFP infection at a genomic MOI of 1 × 10 4 (approximately 10 ng of IL10 from 1 × 10 6 HFT13-hNSCs at 2 days posttransduction), were initially analyzed. Consequently, 10 ng of IL10 secreted from 1 × 10 6 HFT13-hNSCs at 2 days posttransduction could be sufficiently obtained by infecting with rAAVr3.45-IL10 vectors at a genomic MOI of 5 × 10 3 at 2 days post-infection (data not shown), which was set as an infection condition for the mRNA microarray analysis.
The mRNA microarray analysis showed that the majority of gene expression induced by rAAVr3.45-IL10 or by rAAVr3.45-mock vectors was altered by less than threefold compared with non-infected HFT13-hNSCs (Figs. 5b, c) , implying that the exogenous IL10 expression or the viral genome insertion, which primarily occurred at nontranscriptionally active sites, may not seriously interrupt the cascade of endogenous gene expression. Scatter plots showing gene expression profiles, in which the genes altered by greater than twofold were designated red dots, confirmed that rAAVr3.45-mediated infection did not cause severely fluctuated cellular transcriptional profiles (Figs. 5b,  c) . Importantly, 64 probes were significantly altered (by greater than twofold) upon rAAVr3.45-IL10 infection (MOI of 5 × 10 3 ) compared with non-infected HFT13-hNSCs, as shown in a hierarchical clustering heatmap (Fig. 5d) . Only 49 genes were related to cellular transcriptional regulation; 35 genes were upregulated, and 14 genes were downregulated (Table S1 ). In the case of HFT13-hNSC infection with rAAVr3.45-mock vectors, 69 probes were significantly altered (by more than twofold) compared with non-infected HFT13-hNSCs (Fig. 5e ). Among the 69 probes, only 25 non-redundant genes were altered by greater than twofold; 10 genes were upregulated, and 15 genes were downregulated (Table S2 ).
Discussion
The integration of viral genomic DNA into the host chromosomes has been regarded as one of the critical safety concerns in virus-mediated gene delivery approaches. In particular, random genomic insertion, which has been frequently observed in retroviral infection, can cause aberrant transcription or the severe disruption of cellular transcriptional pathways, thereby increasing the risk of oncogene activation [45] . The genomic insertion by rAAVr3.45 vectors lacking the rep gene can be anticipated, as it has been observed in previous studies demonstrating the random integration by rep gene-independent mechanisms [46] , presumably due to the interaction of the AAV's genomic ITR with intracellular proteins [47] or the accidental inclusion of the rep protein during viral packaging or infection [48] . Based on numerous previous reports, random viral genomic insertion by rAAVr3.45 vectors may not carry excessive risk for clinical applications because AAVmediated gene therapy trials have not been associated with malignancies in several human applications [46] . To address the safety concerns of AAV genome insertion, as suggested in many previous reports, whether genome integration by rAAVr3.45 vectors preferably occurs in nontranscriptionally active sites must be extensively studied in the future [46, 49] .
The HFT13-hNSCs secreting IL10 will potentially be employed as ex vivo cellular therapeutics for the treatment of a variety of neurological disorders [30, 31] . Transplanting NSCs can induce therapeutic effects in the injured central nervous system not only through the replacement of injured cells [50] but also through bystander effects, such as the regulation of the immune responses to protect damaged or infused neural cells [51] [52] [53] . The early activation of immune responses after ischemia or neurodegenerative injuries, which prevents bacterial/viral infection and removes necrotic cells, has been known to cause fatal effects, such as permanent neuronal damage [54] . In this context, the cytokine IL10, an immunomodulator that can suppress inflammatory responses or the maturation of dendritic cells [30, 55] , can retard the acute immune responses at early stages to potentially provide more opportunity to treat the ischemia or neurodegenerative injuries. Provoking inflammation in a sustained manner by overexpressing IL10 has been highly crucial to delay the phase of neonatal HI brain injury [56, 57] , demonstrating IL10′s neuroprotective properties against HI neuronal death [26, 27] . Thus, modulating the early immune responses by inducing IL10 secretion from transplanted cells is expected to promote the survival rates of implanted cellular therapeutics and their successful grafting with the host for activating tissue-regenerative mechanisms. Here, injecting IL10-expressing HFT13-hNSCs resulted in significantly reduced infarction volume and substantial improvement of neurological deficits in a HI brain injury animal model, whereas GFP-expressing HFT13-hNSCs did not exhibit therapeutic effects. This observation is consistent with previous studies demonstrating insufficient therapeutic outcomes when hypoxic brain-injured animals received NSCs alone [58, 59] .
The lack of severe disruption of endogenous gene expression in IL10-expressing HFT13-hNSCs compared with cells infected by rAAVr3.45-mock vectors may have been because the secretion of IL10 is inherently involved in a variety of cellular transcriptional regulatory mechanisms [60] , especially upon hypoxic injury [27] . Based on Kyoto Encyclopedia of Genes and Genomes (KEGG) mapping, the genes that were altered over twofold after rAAVr3.45-IL10 infection were involved in forkhead box protein O1 (FOXO1) activity, cytokine-cytokine receptor interaction, and other human disease-related pathways ( Figure S4A ), which regulate gene expression affecting biological processes such as the cell cycle, differentiation, proliferation, apoptosis, and innate immune responses [61] . The exogenous expression of IL10 ( > 3-fold) by rAAVr3.45-IL10 infection resulted in the downregulation ( > 2-fold) of pololike kinase 4 (PLK4), which reduces the number of centrosomes by arresting cells in G1, thereby possibly serving as a cancer treatment strategy [62] . Infecting HFT13-hNSCs with rAAVr3.45-mock primarily altered the pathways involved in metabolism, natural killer (NK) cell-mediated cytotoxicity, and microRNA expression ( Figure S4B ).
Variations in microRNA expression are typically related to the repression of tumor-suppressor gene expression or the increased risk of oncogene activation in different stages of cancers [63] . However, the safety concerns associated with rAAVr3.45-mediated gene delivery approaches may be mitigated compared with those with other viral vectors because the deviations in the cellular transcriptional profiles after rAAVr3.45 infection were not severe (mostly less than twofold deviations). Further studies on safety concerns, including tumorigenicity tests with infected cells or teratoma formation of transplanted hNSCs [64] , must be performed to assure the therapeutic potential of rAAVr3.45 vectors for human gene therapy applications.
Conclusion
The potential of rAAVr3.45 vectors as gene therapy agents for safely and efficiently infecting hNSCs (HFT13-hNSCs) was demonstrated in this study. No severe safety concerns were observed with rAAVr3.45-mediated HFT13-hNSC genetic stimulation. No mycoplasma contamination, no emergence of replication-competent viruses in final cell suspensions, no substantial residues of free viral samples in cell suspensions, a low frequency of viral genome insertion into the host chromosome, and no dramatic disturbance in endogenous transcriptional profiles were observed. Furthermore, transduction by rAAVr3.45 encoding IL10 induced the secretion of IL10 into the extracellular environment, and IL10 is anticipated to function as an immunomodulator at lesion sites. As a result, rAAVr3.45-mediated IL10-expressing HFT13-hNSCs provided therapeutic effects (i.e., reduction in infarction volume and improvement of scores in neurological function tests) for neonatal HI brain injury animal models. The combination of rAAVr3.45-mediated gene delivery with clinically relevant hNSCs will synergistically boost the therapeutic potential of gene and cell therapy trials, ultimately providing highly efficient ex vivo cellular therapeutics for the treatment of many neurological disorders, such as ischemic brain injuries, spinal cord injuries, and acquired/inherited neural diseases.
Materials and methods

Cell culture
Three different cell types, AAV-293, HEK293T, and hNSCs, were utilized in this study. The AAV-293 (Agilent Technologies, Palo Alto, CA) cells, which are genetically transformed from embryonic human kidney cells (i.e., HEK293T cells) to express the adenoviral E1 gene, were used to prepare high titers of rAAV vectors. Both AAV-293 and HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Corning, Corning, NY) with 10% fetal bovine serum (FBS; Corning) and 1% penicillin and streptomycin (P/S; Thermo Fisher Scientific, Waltham, MA) at 37°C and 5% CO 2 . The HEK293T cells were used for testing viral infectious titers. The hNSCs were derived from the telencephalon and have been referred to as HFT13 (or as HFT13-hNSCs in this study) [24] , and they were cultured in DMEM/F12 supplemented with N-2 (1% (v/v); Thermo Fisher Scientific), 8 μg/mL heparin (Sigma-Aldrich, St. Louis, MO), 20 ng/mL fibroblast growth factor-2 (FGF-2; R&D Systems, Minneapolis, MN), 10 ng/mL leukemia inhibitory factor (LIF; Sigma-Aldrich), and 2% P/S at 37°C and 6.5% CO 2 .
Production of rAAVr3.45 vectors
Three different rAAV serotypes, rAAV2, and rAAV5, and rAAVr3.45, were packaged and used to evaluate the safety and efficacy of using rAAVr3.45 as a gene carrier to prepare genetically modified HFT13-hNSCs. Four different types of rAAVr3.45 vectors, which, respectively, carried the gene(s) encoding human IL10 (rAAVr3.45-IL10), GFP (rAAVr3.45-GFP), both IL10 and GFP (rAAV-IL10-IRES-GFP), and no transgene (rAAVr3.45-mock) under the control of the CMV promoter, were packaged using a calcium phosphate transfection method as previously described [12, 22] . Briefly, equal quantities of three plasmids (17 μg each), including pAAVr3.45 carrying rep2-cap r3.45, plasmids carrying transgenes (i.e., IL10, GFP, IL10-IRES-GFP, or mock) flanked by ITRs, and an adenoviral helper plasmid (pHelper; Stratagene, La Jolla, CA), were complexed with calcium ions to efficiently transfect AAV-293 cells cultured in 15-cm tissue culture dishes. The backbone plasmids pAAV-CMV and pAAV-CMV-IRES-GFP, each with a multiple cloning site (MCS) downstream of CMV, were purchased from Cell Biolabs, Inc. (San Diego, CA), and each transgene (i.e., GFP or IL10) was cloned into the MCS site. At 48 h post-transfection, adenovirus-free rAAVr3.45 samples were obtained from cellular lysates by three freeze-thaw cycles and treated with benzonase nuclease (Sigma-Aldrich; 10 units/mL lysate) for 30 min to exclude free genomic fragments. The viral samples in lysates were purified by the iodixanol (OptiPrep, Alere Technologies AS, Oslo, Norway)-based density-gradient method using ultra-centrifugation (360,000 × g force; Type 100 Ti rotor, Beckman Coulter, Brea, CA) for 2 h at 18°C. The resulting purified samples were buffer-exchanged into 1× phosphate buffered saline (PBS) containing 0.01% (v/v) Tween-20 (Sigma-Aldrich) using Amicon tubes (Ultra-15; 10,000 MWCO, Millipore, Billerica, MA). A portion of each harvested viral sample was treated with a deoxyribonuclease (DNase I) to selectively quantify nuclease-resistant genomic titers (i.e., vectors with fully intact capsid) by qPCR (Mini Opticon, Bio-Rad, Hercules, CA) using SYBR Green master mix (Thermo Fisher Scientific).
Mycoplasma detection test
Mycoplasma contamination tests for viral solutions and conditioned medium (HFT13-hNSCs) were conducted using an e-Myco TM VALiD Mycoplasma PCR kit (Intron Biotechnology, Seongnam, Korea). Briefly, each sample was incubated at 95°C for 10 min and vortexed for 10 s, and its supernatants were collected in fresh tubes by centrifuging at 13,000 rpm (16,600 × g) for 2 min. Subsequently, 15 μL of ultrapure water (Thermo Fisher Scientific) and 5 μL of each supernatant were mixed in tubes containing e-Myco TM VALiD Mycoplasma PCR Premix, which includes primer sets to specifically detect mycoplasma, internal control DNA, and DNA polymerase. The PCR was carried out with i-StarTaq TM DNA polymerase, and the products were analyzed by electrophoresis.
Examination of the duration of cellular transduction
The duration of transgene expression from HFT13-hNSCs or HEK293T cells transduced by rAAVr3.45-GFP vectors was examined by monitoring the percentage of GFPpositive cells for over 100 days. Both HEK293T (1 × 10 6 cells) and HFT13-hNSCs (1 × 10 6 cells) were plated in six-well tissue culture plates (TCPs; Falcon, Los Angeles, CA) and then transduced with rAAVr3.45 vectors at a genomic MOI of 1 × 10 3 (for HEK293T) or 1 × 10 4 (for HFT13-hNSCs). Two wild-type serotypes carrying GFP, rAAV2, and rAAV5, were utilized to transduce HEK293T cells as control sets, but no control viral serotypes could be used in HFT13-hNSC transduction due to the inherently non-permissive features of the rAAV2 and rAAV5 vectors in HFT13-hNSCs (no apparent GFP levels could be detected). Both cells were continuously subcultured over 28 days, and the percentage of GFP-positive cells out of the total number of cells, which were collected at the cell-passaging time points, was quantified by flow cytometry at the Yonsei University College of Medicine Medical Research Center (LSRII, BD Biosciences, San Jose, CA).
Detection of rc-AAV vectors
The presence of rc-AAV vectors remaining in viral or cellular solutions was examined. Three different AAV vectors carrying GFP, including rAAV2, rAAV5, and rAAVr3.45, were used at a genomic MOI of 1 × 10 3 to transduce HEK293T cells (1 × 10 6 ) in six-well TCPs. rc-AAV2 carrying the wild-type AAV2 viral genome (i.e., rep2 and cap2) was used as a positive control. At 12 h post-infection, cells were cultured with adenovirus serotype 5 (Ad5) for 48 h, harvested by scraping, and lysed by 3 freeze-thaw cycles. To quantify the genomic titers of rc-AAVr3.45 vectors, Ad5 was inactivated at 60°C for 30 min, and two primers, 5′-CATGGGAAAGGTGCCAGACG-3′ and 5′-ACCATCGGCAGCCATACCTG-3′, were designed to titer the rep genes on the viral genomes of replication-competent vectors in the lysates (qPCR; Bio-Rad). To further confirm the presence of rc-AAV, an additional round of HEK293T cell infection was performed using the viral samples in the cell lysates and Ad5, and all processes to amplify the rep genes were conducted identically to the first round of cellular infection.
Examination of viral residues in final cell suspensions
The presence of viral residues remaining in the HFT13-hNSC suspensions was examined by measuring the percentage of the GFP-positive HEK293T cells, which were infected by the free AAV vectors possibly remaining in HFT13-hNSC suspensions. The HFT13-hNSCs in the final suspension were rinsed three times with fresh 1× Hanks's balanced salt solution containing 10 mM HEPES, pH 7.5 (H-H buffer; Thermo Fisher Scientific) to exclude free viral vectors floating in the medium, and two sets of supernatant collected at each rinsing step were used to transduce HEK293T cells (2 × 10 5 ; 12-well TCPs). The HEK293T cells were utilized due to their highly permissive property to the AAVr3.45 variant. The percentage of GFPpositive cells was quantified 3 days after infection by flow cytometry (LSRII).
Analysis of genomic insertion
To further analyze the chromosomal insertion of AAV viral genomes, NGS analysis of the whole chromosomal DNA of HFT13-hNSCs was performed using an Illumina HiSeqX sequencer (Illumina, San Diego, CA). HFT13-hNSCs infected by rAAVr3.45 were grown for 1 month; the GFP-positive cells, in which the viral genome was assumed to be integrated, were sorted using fluorescence-activated cell sorting, and their chromosomal DNA was isolated. This DNA was sequenced by the Macrogen company (Seoul, Korea) using the HiSeqX platform (Illumina, San Diego, USA). The genomic sequences obtained by the NGS analysis were further examined by the alignment tool BWA-0.7.12 and SAMTools 0.1.19 with reference human genome assembly (hg19).
mRNA microarray analysis
To investigate the variations of endogenous gene expression after viral infection, the microarray analysis of the messenger RNA isolated from infected HFT13-hNSCs was conducted using Affymetrix GeneChip® Human Gene 2.0 ST Arrays (Affymetrix, Santa Clara, CA) by the Macrogen company (Seoul, Korea). Briefly, mRNA was extracted from HFT13-hNSCs (1 × 10 6 ) infected by rAAVr3.45-IL10 or rAAVr3.45-mock, and the gene expression levels of each set were normalized to those obtained from naive HFT13-hNSCs (i.e., no infection). Complementary DNA (cDNA) was synthesized using the GeneChip WT (Whole Transcript) amplification kit (Affymetrix) according to the manufacturer's protocol, and the sense cDNA was then fragmented and biotin-labeled with TdT (terminal deoxynucleotidyl transferase) using the GeneChip WT Terminal labeling kit (Affymetrix). Approximately 5.5 μg of each labeled DNA target was hybridized to the Affymetrix GeneChip Array at 45°C for 16 h. The hybridized arrays were washed and stained on a GeneChip Fluidics Station 450 and scanned on a GCS3000 Scanner (Affymetrix). All data analysis was performed using Affymetrix® GeneChip Command Console® Software (AGCC, Affymetrix).
Active caspase-3 immunostaining
HFT13-hNSCs dissociated from each neurosphere were cytocentrifuged at 1000 rpm for 3 min using a Cytospin® 3 (Thermo Fisher Scientific) to stain apoptotic HFT13-hNSCs at 3 days post-infection. The cells were fixed with 4% paraformaldehyde (PFA) in PBS for 10 min, rinsed three times with PBS, and blocked with 10% normal horse serum (Vector, Burlingame, CA) in PBS containing 0.2% Triton X-100 and 3% bovine serum albumin (BSA; Sigma) at room temperature for 1 h. The resulting cells were incubated with rabbit anti-cleaved caspase-3 antibody (1:250, BD Biosciences) at 4°C overnight, then incubated with rabbit IgG-Texas Red (1:180, Vector). The nuclei were stained with DAPI (Vector). Marker-positive cells, of which five random fields of view were acquired using a fluorescence microscope (BX51, Olympus, Center Valley, PA), were manually counted to quantify the percentages of apoptotic HFT13-hNSCs out of the total DAPI-positive cells.
Western blotting for IL10 secreted from HFT13-hNSCs IL10 expressed by HFT13-hNSCs infected by rAAVr3.45-IL10-IRES-GFP vectors was detected by western blotting. Both the IL10 secreted from infected HFT13-hNSCs and the IL10 remaining in the cells were analyzed. Briefly, both IL10 samples, which were respectively obtained from the supernatant of HFT13-hNSCs (infected at a genomic MOI of 1 × 10 4 ) and from the lysates of HFT13-hNSCs, were mixed with a tissue protein extraction reagent (Thermo Fisher Scientific) and protease inhibitors (Sigma-Aldrich). The IL10 extracted from each sample was separated using 4-15% Mini-PROTEAN TGX precast gels (Bio-Rad) and specifically detected by rabbit anti-IL10 (1:200 dilution; Santa Cruz, Dallas, TX). Signals were recognized by peroxidaseconjugated anti-rabbit secondary antibodies (1:20,000 dilution; Jackson ImmunoResearch, West Grove, PA). β-Actin was detected by mouse anti-β-actin (1:1000; Sigma-Aldrich) followed by anti-mouse secondary antibodies (1:20,000; Jackson ImmunoResearch). All antibody-specific bands were visualized with a Super Signal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific), and images were acquired using an ImageQuant LAS 4000 Mini biomolecular imager (GE Healthcare, Buckinghamshire, UK).
Quantification of IL10 secreted from HFT13-hNSCs
The IL10 secreted from HFT13-hNSCs was detected by a BD™ Cytometric Bead Array (CBA, BD Biosciences) according to the manufacturer's protocol and quantified by flow cytometry (LSRII, BD Biosciences). Briefly, the conditioned medium containing soluble IL10 secreted from HFT13-hNSCs was collected at 2 or 5 days post-transduction, diluted (1:100), and mixed with capture beads containing phycoerythrin (PE) fluorescence reagents (BD Biosciences). After gentle centrifugation at 200 × g for 5 min, the beads associated with IL10 cytokines were resuspended in 50 μL of wash buffer solution (BD Biosciences), and the fluorescence intensity of PE emitted from each sample was measured using flow cytometry (LSRII). A standard curve was fitted based on the concentration of human IL10 protein (2500 pg/mL; BD Biosciences) that was serially diluted (1, 1/2, 1/4, 1/8, 1/16, 1/32, 1/64, 1/128, and 1/256). The concentration of IL10 secreted from HFT13-hNSCs was analyzed using FCAP Array TM v3.0 software (BD Bioscience) and normalized to the number of cells that were initially suspended in each TCP. The immunomodulatory ability of IL10-secreting HFT13-hNSCs was determined by quantifying lipopolysaccharide (LPS; 10 or 100 ng/mL; Sigma-Aldrich)-induced TNF-α production from microglial cell line (SIM-A9) using mouse TNF-α ELISA kit (R&D Systems).
Animal model of neonatal HI brain injury
A unilateral HI brain injury was induced in ICR mice at postnatal day (PND) 7. The right common carotid artery was exposed and permanently ligated with 6-0 surgical silk under isoflurane anesthesia, followed by 90 min of exposure of mice to a hypoxic atmosphere (8% oxygen and 92% nitrogen gas) at 37°C on a warm pad [65] . All procedures were approved by the Institutional Animal Care and Use Committee at Yonsei University College of Medicine.
Transplantation of IL10-expressing HFT13-hNSCs
The injured animals were randomly assigned to three groups: the ones that were transplanted with (i) IL10-expressing HFT13-hNSCs or (ii) GFP-expressing HFT13-hNSCs and (iii) the ones that were treated with H-H buffer (vehicle; Hanks's balanced salt solution containing 10 mM HEPES (Gibco), pH 7.4) at 3 days after injury (at PND 10). Total 8 × 10 5 HFT13-hNSCs (8 μL of 100,000 cells) were injected into the ischemic core of the ipsilateral hemisphere using a glass micropipette, as done in a previous study [66] . All mice were intraperitoneally injected with cyclosporine (10 mg/kg per day; Sandimmune, Novartis Korea, Seoul) 1 day prior to transplantation.
Neurological function test
Neurological tests were performed at 1, 2, 3, and 4 weeks post-transplantation using the modified neurological severity score test. Neurological functions were monitored as follows: (a) the reflex to keep upright and extend its forelimbs when the mouse was held by its tail; (b) the reflex to turn over to rest in the normal position with four feet on the table when its body was tilted; (c) the reflex to place the hind limbs back on the table when it was hung over the table edge; (d) the reflex to spread its fore toes and hind toes when it was suddenly dropped on the board. Each test was scored as "0" if the reflex was normal and "1" if not. Animals were graded on a scale from 0 to 7 (0 = normal score; 7 = maximal deficit score). All in vivo experiments were performed double blinded.
Infarction volume measurement
The variations in infarction volume were assessed to determine the therapeutic efficacy of HFT13-hNSC injection. The brain was dissected, fixed overnight in 4% PFA in 0.1 M PIPES buffer (Sigma, St. Louis, MO, USA), and coronally cryosectioned on a freezing cryostat at 16 μm thickness. The sections were stained with hematoxylin (Vector, Burlingame, CA, USA) and eosin-Y (Sigma, St. Louis, MO, USA) and observed under a virtual microscope (Olympus BX51, Tokyo, Japan). The measurement of infarction volume was conducted with the brain sections dissected at 4 weeks post-transplantation (n = 8-9 per group). The infarction area was measured by ImageJ (Broken Symmetry Software, NIH), and the infarction volume was expressed as a percentage of the contralateral volume of the brain by using the following formula: [67, 68] ðvolume of the contralateral hemisphereÞÀ ðvolume of the remaining ipsilateral hemisphereÞ ðvolume of the contralateral hemisphereÞ Â 100
Immunofluorescence staining of brain sections
For immunofluorescence staining, the sections were blocked with 3% BSA (Sigma), 10% normal donkey serum (Jackson ImmunoResearch), and 3% Triton X-100 (Sigma) in PBS for 1 h. The sections were incubated with chicken anti-GFP (1:500 dilution; Abcam, Cambridge, UK), goat anti-human IL10 (hIL-10, 1:100 dilution; R&D Systems, Minneapolis, MN), and mouse anti-human-specific cytoplasm (STEM121, 1:500 dilution; Takara Bio Inc., Shiga, Japan) antibodies at 4°C overnight and visualized with Alexa Fluor® 488-, Alexa Fluor® 647-and Cy3-conjugated secondary antibodies (Jackson ImmunoResearch) for 1 h at 37°C, followed by counterstaining with VECTASHIELD mounting medium with DAPI. Images were acquired by a confocal microscope (LSM700, Carl Zeiss, Germany).
Statistics
All experiments were performed at least in triplicate, and the experimental data are presented as the mean ± the standard deviation (SD) or standard error of the mean (SEM). A one-way analysis of variance (ANOVA) with a post hoc Dunnett's test, the Kruskal-Wallis test with a post hoc Dunn's test, or Student's t-test using the SPSS 24.0 software package (IBM Corporation, Somers, NY) was used to test for significant differences.
